Biomarkers for assessment of Skeletal maturation
DOI:
https://doi.org/10.61841/g0jne397Keywords:
Biomarkers, Skeletal maturation, OrthopaedicAbstract
While making orthodontic treatment plans, the most important objective is to correct skeletal discrepancies by utilising the growth potential of the patient so that the most favourable results could be achieved. Response to orthopaedic treatment modalities is maximum during the peak of adolescent growth spurt. The correct identification of the prepubertal and postpubertal growth phases on an individual basis is very important in orthodontic diagnosis and treatment planning. [2] Orthopaedic treatment of patients with Class III malocclusion and rapid maxillary expansion achieves maximum efficacy when performed at a pre-pubertal growth phase. On the other hand, in Class II subjects, the amount of supplementary mandibular growth induced by functional appliances appears to be significantly greater when the treatment is performed during the pubertal growth phase.
Downloads
References
1. Tripathi T, Gupta P, Rai P. Biochemical markers as skeletal maturity indicators. Int J Orthod Rehabil [serial online] 2017 [cited 2020 Jul 23];8:60-6.
2. Hunter CJ, The correlation of facial growth with body height and skeletal maturation at adolescence. Angle Orthod 1966; 36: 44-54.
3. Green LJ, Interrelationship among height, weight, and chronological, dental, and skeletal age. Angle Orthodox 1961; 31: 189-93.
4. Fishman LS, Chronological versus skeletal age, an evaluation of craniofacial growth. Angle Orthod 1979; 49: 181-9.
5. Hägg U, Taranger J, Maturation indicators and the pubertal growth spurt. Am J Orthod 1982; 82:299-309.
6. Sushma Dhiman, Sandhya Maheshwari, Sanjeev K. Verma. Assessment of maturity in orthodontics: A review. Journal of Advanced Clinical & Research Insights (2015), 2, 100– 103
7 Giuseppe Perinetti; Lorenzo Franchi; Attilio Castaldo; Luca Contardo .Gingival crevicular fluid protein content and alkaline phosphatase activity in relation to pubertal growth phase. Angle Orthod (2012) 82 (6): 1047–1052.
8. Gaur A, Maheshwari S, Verma SK. Detection of molecular biomarkers as a diagnostic tool in the planning and progression of orthodontic treatment. J Orofac Sci 2017;9:80-4.
9. WHO International Programme on Chemical Safety Biomarkers in Risk Assessment: Validity and Validation. 2001. Retrieved from http://www.inchem.org/documents/ehc/ehc222.htm.
10. Z Laron. Insulin-like growth factor 1 (IGF-1): a growth hormone. Mol Pathol. 2001 Oct; 54(5): 311–316.
11. Salmon WD, Jr., Daughaday W. A hormonally controlled serum factor that stimulates sulfate incorporation by cartilage in vitro. J Lab Clin Med 1957;49:825–36.
12. Rinderknecht E, Humbel RE. Polypeptides with non-suppressible insulin-like and cellgrowth-promoting activities in human serum: isolation, chemical characterization, and some biological properties of forms I and II. Proc Natl Acad Sci U S A 1976;73:2365-9.
13. Hwa V, Oh Y, Rosenfeld RG. The insulin-like growth factor-binding protein (IGFBP) superfamily. Endocr Rev 1999;20:761–87
14. Werner H. Molecular biology of the type I IGF receptor. In: Rosenfeld RG, Roberts CT, Jr., eds. The IGF system—molecular biology, physiology and clinical applications. Totowa, NJ: Humana Press, 1999:63–88.
15. GEORGIOS D. AGROGIANNIS, STAVROS SIFAKIS, EFSTRATIOS S. PATSOURIS, ANASTASIA E. KONSTANTINIDOU. Insulin-like growth factors in embryonic and fetal growth and skeletal development (Review). Mol Med Rep. 2014 Aug; 10(2): 579–584.
16. Georg Brabant, Alexander von zur Muhlen Christian Wüster, Michael B. Ranke, Jürgen Kratzsch, Wieland Kiess, Jean-Marie Ketelslegers, Lars Wilhelmsen, Lena Hulthén, Bernhard Saller, Anders Mattsson, Jürgen Wilde, Rudolf Schemer, Peter Kann. Serum Insulin-Like Growth Factor I Reference Values for an Automated Chemiluminescence Immunoassay System: Results from a Multicenter Study. Horm Res 2003;60:53–60.
17. A Juul, P Bang, N T Hertel, K Main, P Dalgaard, K Jørgensen, J Müller, K Hall, N E Skakkebaek. Serum insulin-like growth factor-I in 1030 healthy children, adolescents, and adults: relation to age, sex, stage of puberty, testicular size, and body mass index. The Journal of Clinical
Endocrinology & MetabMetabolism 199478(3):744-52.
18. Hizuka, N., Takano, K., Tanaka, I., Asakawa, K., Miyakawa, M., Horikawa, R. & Shizume, K. (198(1987(1987). stimulationinsulin-like growth factor I in human urine. Journal of Clinical Endocrinology and Metabolism, 64, 1309–1312.
19. Hizuka, N., Takano, K., Asakawa, K., Sukegawa, I., Horikawa, R., Yoshizawa, Y., Saito, S. & Shizume, K. (198(1988(1988). IGF-I measurement and its clinical application. Acta Paediatrica Scandinavica, 347(Suppl.), 127–133.
20. Quattrin, T., Albini, C.H., Vandlen, R.L. R.L.R.L., and GillivrayH. (198(1987(1987). tion of urinary somatomedin-C in children with normal and abnormal growth. Journal of Clinical Endocrinology and MetabMetabolism 1168–1171.
21. Yokoya, S., Suwa, S., Maesaka, H.,,H.Tanaka, T. (1988a) Immuno-reactive somatomedin-C/insulin-like growth factor I in urine from normal subjects, pituitary dwarfs, and acromegalics. Pediatric Research, 23, 151–154.
22. Albini, C.H., Quattrin, T., Mills, B., Sherman, B., Johansonn, A. &A.,acGillivray, M.H. (1992). Urinary growth hormone and insulin-like growth factor-I. Clinical Paediatrics, 31, 542–545.
23. Ratcliffe, S.G., Masera, N., Skinner, A.M., Jones, J., Morrell, D., Pan, H., Price, D.A., Preece, M.A., & Clayton, P.E. (1995). Urinary insulin-like growth factor I in normal children: Relationship to age, pubertal status, and urinary growth hormone. Growth Regulation, 5, 53–59.
24. C. M. Hall, M. S. Gill, P. Foster, L. Pennells, V. Tillmann, J. Jones, D. A. Price, and P. E. Clayton. Relationship between serum and urinary insulin-like growth factor-I through childhood and adolescence: their use in the assessment of disordered growth. Clinical Endocrinology (1999) 50,
611–618.
25. Gill, M.S., Whatmore, A.J., Tillmann, V., White, A., Addison, G.M., Price, D.A., & Clayton, P.E. (1997) Urinary IGF and IGF-binding protein-3 in children with disordered growth. Clinical Endocrinology, 46, 483–492.
26. Sinha M, Tripathi T, Rai P, Gupta SK. Serum and urine insulin-like growth factor-1 as biochemical growth maturity indicators. Am J Orthod Dentofacial Orthop. 2016 Dec;150(6): 1020-1027
27. 27. D. C.tCostigan, H. J.da, and and B.oI. Posner.e insulin-like growth factor I (IGF-I) and IGF-II in human saliva. J Clin Endocrinol Metab.1988 May;66(5):1014-8.
28. Masoud M, Masoud I, Kent RL Jr., Gowharji N, Cohen LE. Assessing skeletal maturity by using blood spot insulin-like growth factor I (IGF-I) testing. Am J Orthod Dentofacial Orthop. 2008 Aug;134(2):209-16.
29. Ishaq RA, Soliman SA, Foda MY, Fayed MM. Insulin-like growth factor I: a biologic maturation indicator. Am J Orthod Dentofacial Orthop. 2012 Nov;142(5):654-61.
30. Sapna Jain, Sandhya Jain, Anuradha Deoskar, V S Sai Prasad. Serum IGF-1 levels as a clinical tool for optimizing orthodontic treatment timing.Prog Orthod. 2013 Nov 14;14:46.
31. Nimisha Jain, Tulika Tripathi, S. K. Gupta, Priyank Rai, Anup KanaKanase, andlpa Kalra. Serum IGF-1, IGFBP-3, and their ratio: Potential biochemical growth maturity indicators. Prog Orthod. 2017 Dec;18(1):11.
32. The role of alkaline phosphatase in cartilage mineralization. Golub EE, et al., Bone Miner. 1992.
33. Ujjawal Sharma, Deeksha Pal, and Rajendra Prasad. Alkaline Phosphatase: An Overview. Indian J Clin Biochem. 2014 Jul; 29(3): 269–278.
34. S Krabbe, C Christiansen. Longitudinal study of calcium metabolism in male puberty. I. Bone mineral content and serum levels of alkaline phosphatase, phosphate, and calcium. Acta Paediatr Scand. 1984 Nov;73(6):745-9.
35. Serap Turan, Burcu Topcu, İbrahim Gökçe, Tülay Güran, Zeynep Atay, Anjumanara Omar, Teoman Akçay, Abdullah Bereket. Serum alkaline phosphatase levels in healthy children and evaluation of alkaline phosphatase z-scores in different types of rats. J Clin Res Pediatr Endocrinol. 2011;3(1):7-11.
36. G Perinetti, T Baccetti, L Contardo, R Di Lenarda. Gingival crevicular fluid alkaline phosphatase activity as a non-invasive biomarker of skeletal maturation. Orthod Cranifac Res 2011 Feb;14(1):44-50.
37. Perinetti G, Baccetti T, Di Leonardo B, Di Lenarda R, Contardo L. Dentition phase and chronological age in relation to gingival crevicular fluid alkaline phosphatase activity in growing subjects. Prog Orthod 2011;12:100-6.
38. Dr. Suchita M. Tarvade (Daokar). Dr. Sheetal Ramkrishna, Dr. Sanjay Sarode. Salivary alkaline phosphatase is a biochemical marker for growth prediction. Indian Journal of Basic and Applied Medical Research; June 2015: Vol. 4, Issue 3, P. 17-22.
39. Hegde SS, Revankar AV, Patil AK. Identification of bone-specific alkaline phosphatase in saliva and its correlation with skeletal age. Indian J Dent Res 2018;29:721-5.
40. Fadhlina Irham, Siti Bahirrah. The Level of Alkaline Phosphatase in Saliva as a Biomarker for Pubertal Growth Phase. Advances in Health Science Research, 2017, volume 8, 102:105.
41. Tulika Tripathi, Prateek Gupta, Priyank Rai, Jitender Sharma, Vinod Kumar Gupta, Navneet Singh, and Mahesh Verma. Longitudinal evaluation of the association between insulin-like growth factor-1, bone-specific alkaline phosphatase, and changes in mandibular length. Sci Rep. 2019; 9: 11582.
42. Nora Alhazmi; Carroll Ann Trotman; Matthew Finkelman; Dillon Hawley; Driss Zoukhri; Evangelos Papathanasiou. Salivary alkaline phosphatase activity and chronological age as indicators for skeletal maturity.Angle Orthod (2019) 89 (4): 637–642.
Downloads
Published
Issue
Section
License
Copyright (c) 2020 AUTHOR

This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.